Amedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance
Get Alerts AMED Hot Sheet
Price: $90.96 --0%
EPS Growth %: +2.0%
Financial Fact:
Non-cash compensation: 4.75M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +2.0%
Financial Fact:
Non-cash compensation: 4.75M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q1 EPS of $1.11, $0.21 better than the analyst estimate of $0.90. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $460.61 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.02. Amedisys sees FY2019 revenue of $1.94-1.98 billion, versus the consensus of $1.96 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
- Texas Capital Bancshares (TCBI) Misses Q1 EPS by 12c
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!